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Edited by Barry HalliwellAbstract In the present study, we investigated the mechanism
of nitric oxide (NO) inactivation by endothelial cells. All
experiments were performed in the presence of superoxide
dismutase to minimize the peroxynitrite reaction. Incubation of
the NO donor diethylamine/NO adduct with increasing amounts
of intact cells led to a progressive decrease of the NO
concentration, demonstrating a cell-dependent consumption of
NO. In cell homogenates, consumption of NO critically
depended on the presence of NADPH or NADH and resulted
in the formation of nitrate. Both NO consumption and nitrate
formation were largely inhibited by the heme poisons NaCN and
phenylhydrazine as well as the ﬂavoenzyme inhibitor diphenylene
iodonium. Further characterization of this NO consumption
pathway suggests that endothelial cells express a unique
membrane-associated enzyme or enzyme system analogous to
the bacterial NO dioxygenase that converts NO to nitrate in a
NAD(P)H-, ﬂavin- and heme-dependent manner.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nitric oxide (NO) bioavailability is critically determined by
both the rate of synthesis and decay. In aqueous aerobic so-
lutions, NO decay is solely due to autoxidation yielding nitrite
as end-product [1–3]. At physiologically relevant concentra-
tions of NO, the autoxidation reaction is rather slow, but in
hydrophobic compartments such as the cell membrane the
reaction is 300-fold accelerated because of increased parti-
tioning of NO and oxygen within the membrane interior [4].
Nonetheless, the autoxidation reaction is still not fast enough
to solely account for the extremely short biological half-life of
NO (1–2 s [5,6]), indicating that additional, cell-dependent
mechanisms are involved in the inactivation of NO. One well
known pathway contributing to the rapid inactivation of NO
in tissues is through its reaction with superoxide yielding* Corresponding author. Fax: +43-316-380-9890.
E-mail address: kurt.schmidt@uni-graz.at (K. Schmidt).
Abbreviations: DEA/NO, diethylamine/NO adduct; DPI, diphenylene
iodonium; DTPA, diethylenetriamine pentaacetic acid; ETYA, eico-
satetraynoic acid; NO, nitric oxide; SOD, superoxide dismutase
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oxide, mainly catalyzed by NAD(P)H oxidases [8], particularly
contributes to the inactivation of NO under pathological
conditions [9]. NO also reacts very rapidly with hemoglobin
but this reaction is limited by the diﬀusion of NO into ery-
throcytes [10,11], questioning whether hemoglobin substan-
tially contributes to the biological inactivation of NO [12]. In
the last few years, several other NO consumption pathways
have been identiﬁed, including lipoxygenases [13,14], prosta-
glandin H synthase [15], peroxidases [16], cytochrome c oxi-
dase [17], and catalase [18]. While inactivation of NO by these
enzymes ultimately results in the formation of nitrite, oxida-
tion of NO to nitrate by dihydrolipoamide dehydrogenase [19],
a ﬂavohemoglobin-like NO dioxygenase [20,21] and a yet un-
identiﬁed protein [22] has also been demonstrated.
In the course of our on-going studies on endothelial NO/
cyclic GMP signaling, we have observed a pronounced enzy-
matic inactivation of NO that was insensitive to superoxide
dismutase (SOD) and thus not attributable to the peroxynitrite
reaction. The aim of this study was to elucidate the mecha-
nism(s) underlying vascular endothelial NO consumption that
may play a pivotal role in cardiovascular diseases associated
with endothelial dysfunction.2. Materials and methods
2.1. Materials
Cell culture media, antibiotics and fetal calf serum were purchased
from PAA Laboratories GmbH (Linz, Austria). Diethylamine/NO
(DEA/NO) was from Alexis (Gr€unberg, Germany); stock solutions
were prepared in 10 mM NaOH. All other chemicals including SOD
(from bovine erythrocytes, 2500–7000 units/mg protein, product
number S 2515) were from Sigma (Vienna, Austria).
2.2. Cell culture
Porcine aortic endothelial cells were isolated as described previously
[23] and cultured at 37 C and 5% CO2 up to 3 passages in Dulbecco’s
modiﬁed Eagle’s medium, containing 10% heat-inactivated fetal calf
serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1.25 lg/ml
amphotericin B.
2.3. Preparation of cell suspensions, homogenates and subcellular
fractions
For experiments with intact cells, endothelial cells from 5 to 10 petri
dishes (5 106 cells/per dish) were harvested, washed with phos-
phate-buﬀered saline and resuspended in incubation buﬀer (50 mM
Tris/HCl, pH 7.4, containing 100 mMNaCl, 5 mMKCl, 1 mMMgCl2,
and 3 mM CaCl2). For preparation of homogenates, endothelial cellsblished by Elsevier B.V. All rights reserved.
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Fig. 1. NO consumption by intact endothelial cells. (A) Representative
recordings of the NO concentration proﬁles obtained upon decom-
position of 1 lMDEA/NO in buﬀer containing 1000 U/ml SOD in the
absence (a) and presence of 1.5 106 (b), 3 106 (c), 4.5 106 (d),
6 106 (e), and 9 106 cells/ml (f). (B) Maximal concentrations of NO
obtained following addition of 1 lM DEA/NO to buﬀer containing
1000 U/ml SOD and cells as indicated. (C) Maximal concentrations of
NO obtained following addition of 1 lM DEA/NO to buﬀer con-
taining 4.5 106 cells/ml and SOD as indicated. Data shown in (B) and
(C) are mean valuesS.E.M. (n ¼ 3).
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Fig. 2. NO consumption by endothelial cell homogenates. (A) Rep-
resentative recordings of the NO concentration proﬁles obtained upon
decomposition of 1 lM DEA/NO in buﬀer, homogenates (0.7 mg/ml
protein) or cell suspensions (6 106 cells/ml). Experiments were per-
formed in the presence of 1000 U/ml SOD and, where indicated, 0.2
mM NADPH or NADH. (B) Maximal concentrations of NO obtained
following addition of 1 lM DEA/NO to buﬀer or homogenates (0.35–
2.3 mg/ml protein) in the presence of 1000 U/ml SOD and 0.2 mM
NADPH. Results obtained with intact cells (Fig. 1B) are shown as
dotted line. (C) Maximal concentrations of NO obtained following
addition of 1 lM DEA/NO to homogenates (1 mg/ml protein), con-
taining 0.2 mM NADPH and SOD as indicated. Data shown in (B)
and (C) are mean valuesS.E.M. (n ¼ 3).
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buﬀered saline, resuspended in 1 ml of ice-cold incubation buﬀer and
disrupted by sonication. Where indicated, homogenates were centri-
fuged for 30 min at 30 000 g to obtain particulate and cytosolic
fractions. Protein was determined with the Bradford [24] method using
bovine serum albumin as standard.
2.4. Electrochemical detection of NO
NO concentrations were measured with a Clark-type electrode (Iso-
NO, World Precision Instruments, Mauer, Germany) under constant
stirring in an open, thermostated vessel (37 C) containing 1 ml of
incubation buﬀer (see above) and cells or homogenate as indicated.
Unless otherwise stated, all experiments were performed in the pres-
ence of 1000 U/ml of SOD. After equilibration or preincubation with
the inhibitors (10 min), DEA/NO (ﬁnal concentration 1 lM) was ad-
ded and the concentration of NO monitored over time. Where indi-
cated, experiments were performed in the presence of NADPH or
NADH, which was added immediately before addition of DEA/NO.
2.5. Determination of nitrite and nitrate
The formation of nitrite and nitrate from DEA/NO (10 lM) was
determined by allowing the donor (half-life¼ 2.1 min at pH 7.4 and 37
C) to decompose for 1 h at 37 C in 0.4 ml incubation buﬀer, con-
taining 500 U/ml of SOD, 0.2 mM of NADPH, and homogenates as
indicated, followed by determination of nitrite and nitrate using a
spectrophotometric method adapted from Miranda et al. [25]. Where
indicated, homogenates were preincubated with inhibitors for 10 min
at 37 C prior to the addition of NADPH and DEA/NO. For thedetermination of nitrite, 0.3 ml of the incubated samples was mixed
with 0.3 ml of Griess reagent (20 mg naphthylethylenediamine and 200
mg sulfanilamide in 5% (v/v) HCl) and incubated for 15 min at 37 C.
Following centrifugation at 20,000 g (5 min), 0.2 ml of the super-
natants was transferred into a 96-well plate for the photometrical de-
termination of nitrite. Subsequently, 0.1 ml of a saturated VCl3
solution (40 mg in 5 ml of 1 N HCl) was added to each well and the
absorbance measured after a 90-min incubation at 37 C to determine
the concentration of nitrite plus nitrate, from which the nitrite con-
centration was subtracted to obtain the concentration of nitrate. Ni-
trite and nitrate standards were prepared in buﬀer containing SOD and
NADPH and assayed as described above. Data obtained with homo-
genates were corrected for endogenous nitrite and nitrate determined
in the absence of DEA/NO.3. Results
3.1. NO consumption by intact cells
Consistent with the known rates of NO release from DEA/
NO and autoxidation [26], decomposition of 1 lM DEA/NO
in buﬀer resulted in a transient increase in the NO concen-
tration that reached a peak of 0.85 lM after 3 min and then
declined to 0.48 lM within 10 min (Fig. 1A, curve a). In the
presence of 1.5 106 cells/ml (curve b), the peak was smaller
(0.63 lM) and followed by a more pronounced decline in NO
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gressively enhanced the consumption of NO such that only a
marginal and short-lasting increase in NO (peak 0.1 lM,
duration <4 min) was obtained in the presence of 9 106 cells/
ml (curve f). As evident from Fig. 1B, there was an inverse,
almost linear correlation between the amount of endothelial
cells and the peak concentration of NO, demonstrating that
the decline in the NO peak can serve as a reliable measure for
NO consumption. To minimize superoxide-mediated NO in-
activation, these experiments were performed in the presence
of 1000 U/ml SOD. As shown in Fig. 1C, the peak concen-
tration of NO was not aﬀected when SOD was increased to
2000 or 5000 U/ml, demonstrating that the concentration of
SOD applied in this study (1000 U/ml) is suﬃcient to out-
compete the peroxynitrite reaction.
3.2. NO consumption by homogenates
Consumption of NO was also observed with endothelial cell
homogenates, but was less pronounced than with intact cells
(Fig. 2A). However, addition of NADPH (0.2 mM) enhanced
NO consumption by homogenates to a level comparable to
that of intact cells without aﬀecting NO concentrations mea-
sured in buﬀer or cell suspensions (data not shown). A similar,
albeit less pronounced eﬀect was observed when NADH (0.2
mM) was used instead of NADPH. Fig. 2B shows the con-
centration-dependent eﬀect of endothelial cell homogenates on
the peak concentrations of NO measured in the presence of 0.2
mM NADPH. For comparison, the results obtained with in-
tact endothelial cells (cf. Fig. 1B), normalized to cellular pro-
tein, are shown as dotted line. At equivalent protein
concentrations, intact cells and homogenates showed virtually
identical NO consumption, indicating that the loss of NO
consuming activity upon cell homogenization is due to dilution
of an essential nucleotide cofactor. Therefore, all further ex-
periments were routinely performed in the presence of 0.2 mM
NADPH. As in intact cells, 1000 U/ml of SOD was suﬃcient to
prevent superoxide-mediated NO inactivation (Fig. 2C).
As shown in Fig. 3, the eﬀect of cell homogenates was vir-
tually abolished after heat-denaturation, suggesting the in-
volvement of a heat-labile factor, presumably a protein. The0
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Fig. 3. Eﬀects of inhibitors on NO consumption by cell homogenates.
Homogenates (1.4 mg/ml protein) were preincubated for 10 min at 37
C in the presence of 1000 U/ml SOD and, where indicated, 0.1 mM
DPI, 0.1 mM phenylhydrazine (PH), or 1 mMNaCN (CN). Following
addition of 0.2 mM NADPH and 1 lM DEA/NO, the maximal con-
centration of NO was determined. For heat-denaturation, the homo-
genates were boiled for 10 min prior to the addition of SOD, NADPH
and DEA/NO. Data are mean valuesS.E.M. (n ¼ 3–5).essential role of NAD(P)H and oxidation of NO to nitrate (see
below) suggested the involvement of ﬂavin and heme con-
taining proteins. Indeed, preincubation of the homogenate for
10 min with the ﬂavoenzyme inhibitor diphenylene iodonium
(DPI) (0.1 mM) or the heme poisons phenylhydrazine (0.1
mM) and NaCN (1 mM) substantially reduced the consump-
tion of NO (Fig. 3). None of the drugs aﬀected the NO signal
measured upon decomposition of DEA/NO in buﬀer (data not
shown). Inhibition of the arachidonic acid cascade by pre-
treatment of homogenates with 0.1 mM mepacrine (peak
concentration 0.09 0.03 lM NO), 0.1 mM eicosatetraynoic
acid (ETYA) (0.11 0.05 lM NO) or 0.1 mM indomethacin
(0.1 0.04 lM NO) was ineﬀective, excluding an involvement
of prostaglandin H synthase and lipoxygenases. Similarly, the
soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (0.1 mM, 0.1 0.02 lM NO) and the Fe2þ
chelator diethylenetriamine pentaacetic acid (DTPA) (0.1 mM,
0.1 0.06 lM NO) had no eﬀect, indicating that neither
scavenging of NO by the ferrous heme bound to soluble gua-
nylyl cyclase nor Fenton chemistry or lipid peroxidationFig. 4. Eﬀects of H2O2 and catalase on NO consumption. (A) Maximal
concentrations of NO obtained following addition of 1 lM DEA/NO
to homogenates (0.35 mg/ml protein), containing 1000 U/ml SOD, 0.2
mM NADPH, and, where indicated, H2O2 (0.1–1 mM) or catalase
(1000 U/ml). (B) Maximal concentrations of NO obtained following
addition of 1 lM DEA/NO to buﬀer, containing 1000 U/ml SOD and,
where indicated, H2O2 (0.1–1 mM) or catalase (1000 U/ml). Experi-
ments were either performed in the absence (hatched columns)
or presence of 0.2 mM NADPH (ﬁlled columns). Data are mean
valuesS.E.M. (n ¼ 3).
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thelial cells.
Since peroxidases were reported to inactivate NO [16], we
studied whether addition of H2O2 or catalase aﬀects the
endothelial consumption of NO. These experiments were per-
formed at lower protein concentrations (0.35 mg/ml) to allow
the detection of both increased and decreased rates of con-
sumption. Addition of H2O2 (0.1–1 mM) to homogenates
enhanced NO consumption (Fig. 4A), but the same eﬀect was
observed in buﬀer containing SOD (Fig. 4B). Omission of
SOD from the buﬀer completely abolished the eﬀect of H2O2
(data not shown), suggesting that the inactivation of NO was
caused by SOD operating in reverse mode, i.e., catalyzing the
formation of superoxide from H2O2 [27]. NO was also con-
sumed by catalase in both homogenate (Fig. 4A) and buﬀer
(Fig. 4B). Since the eﬀects of catalase and SOD/H2O2 were
already observed in the absence of NADPH, neither of these
pathways appears to contribute to the NAD(P)H-dependent
consumption of NO by endothelial cells.
3.3. NO consumption by subcellular fractions
After centrifugation of the homogenate at 30 000 g, about
80% of the NO consuming activity was found in the particulate
fraction (data not shown). At equivalent protein concentra-
tions (0.35 mg/ml), NO consumption by the particulate frac-
tion was substantially higher than by the homogenate, whereas0
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Fig. 5. NO consumption by subcellular fractions. (A) Maximal con-
centrations of NO obtained following addition of 1 lM DEA/NO to
buﬀer, homogenates, particulate (P) and cytosolic fractions (C, 0.35
mg/ml protein, each), containing 1000 U/ml SOD and 0.2 mM
NADPH. Where indicated, proteins were preincubated for 10 min at
37 C in the presence of 0.1 mM DPI or 1 mM NaCN (CN) or ex-
periments performed in the absence of NADPH. (B). Eﬀects of
NADPH and NADH on NO consumption by particulate fractions.
Values are expressed as percentage of NO consumption measured in
the presence of 0.2 mM NADPH. Data are mean valuesS.E.M.
(n ¼ 3).
Fig. 6. Eﬀect of homogenates onnitrite andnitrate formation. (A)Buﬀer
or homogenates (1.0–6.9mg/ml protein) were incubated for 60min at 37
C with 10 lMDEA/NO in the presence of 500 U/ml SOD and 0.2 mM
NADPH, and then nitrite (open circles) and nitrate (ﬁlled circles) were
determined as described in Section 2. (B) Homogenates (4.2 mg/ml
protein) were preincubated for 10 min at 37 C in the presence of 500 U/
ml SOD and, where indicated, 0.1 mM DPI, 0.1 mM phenylhydrazine
(PH), or 1 mM NaCN (CN). Then, 10 lM DEA/NO and 0.2 mM
NADPH (if not otherwise indicated) were added, samples incubated for
60 min, and nitrite (hatched columns) and nitrate (ﬁlled columns) de-
termined. Data are mean valuesS.E.M. (n ¼ 3–5).the cytosolic fraction was virtually inactive (Fig. 5A). The NO
consuming activity of the particulate fraction was markedly
inhibited after preincubation with 0.1 mM DPI or 1 mM
NaCN and virtually abolished in the absence of NADPH. As
shown in Fig. 5B, maximal NO consumption was obtained
with 0.2 mM NADPH and the EC50 was 10 lM. NADH was
slightly more potent than NADPH (EC50  2:5 lM), but the
maximal eﬀect was less pronounced (75% at 20 lM).
3.4. Nitrate formation by homogenates
To get more information on mechanism underlying the
consumption of NO by endothelial cells, we measured the NO
oxidation products, nitrite and nitrate, following decomposi-
tion of DEA/NO (10 lM) in buﬀer and cell homogenates
(Fig. 5). Since the 1000 U/ml of SOD used in the other ex-
periments interfered with the detection of nitrate, the amount
of SOD was reduced to 500 U/ml. Consistent with the well
known NO autoxidation reaction [1–3], the major end-product
of NO degradation in buﬀer was nitrite (10.1 0.5 lM), and
nitrate was barely detectable (0.9 0.3 lM, Fig. 6A). Addition
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the concentration of nitrate up to 6.7 0.6 lM and, con-
versely, diminished the concentration of nitrite to 4.2 1.0
lM. Nitrate was not detectable upon incubations of the ho-
mogenates with 10 mM nitrite, suggesting a direct oxidation of
NO to nitrate. In accordance with the NO consumption data,
DPI (0.1 mM), phenylhydrazine (0.1 mM), NaCN (1 mM) and
omission of NADPH reduced the formation of nitrate by
homogenates (Fig. 6B). Treatment of the homogenates with
0.1 mM ETYA (6.1 0.8 lM nitrate), 0.1 mM indomethacin
(6.6 0.5 lM), 0.1 mM DTPA (5.8 0.4 lM) or the perox-
ynitrite/superoxide scavenger Mn(III)tetrakis(4-benzoic
acid)porphyrin (0.1 mM, 6.2 0.7 lM nitrate) had no eﬀect.
Moreover, modulation of intracellular tetrahydrobiopterin
levels by preincubation of the cells for 24 h with 0.1 mM se-
piapterin (5.8 0.5 lM nitrate) or 50 mM 2,4-diamino-
6-hydroxypyrimidine (6.5 0.6 lM) or preincubation of the
homogenate with 0.1 mM miconazole (6.2 0.4 lM), 0.1 mM
econazole (6.1 0.1 lM), or 1 mM NG-nitro-L-arginine
(6.3 0.5 lM) was ineﬀective, excluding a role of dihydro-
pteridine reductase, cytochrome P450 reductase or NO
synthase in the conversion of NO to nitrate.4. Discussion
In the present study, we demonstrate that endothelial cells
express a considerable NO-consuming activity that is insensi-
tive to SOD and thus not due to the reaction with superoxide.
Consumption of NO was preserved in homogenates supple-
mented with NAD(P)H and resulted in the formation of
nitrate. Lack of nitrate formation upon incubation of homo-
genates with nitrite suggests direct oxidation of NO by a di-
oxygenase. Together with the dependence on NADPH
(EC50  10 lM) and NADH (EC50  2:5 lM), the sensitivity
to DPI, phenylhydrazine and NaCN points to a combined
action of a NAD(P)H:FAD oxidoreductase with a heme pro-
tein. Thus, NO consumption by endothelial cells appears re-
markably similar to the reaction catalyzed by the bacterial
ﬂavohemoglobin, NO dioxygenase [28,29]. A BLASTP ho-
mology search using the protein sequence of E. coli ﬂavohe-
moglobin as template yielded no promising mammalian
analog. Only a minor homology (25%) was found for NADH
cytochrome b5 reductase, but a role of this enzyme can be
excluded, as it is highly speciﬁc for NADH [30,31]. Similarly,
dihydrolipoamide dehydrogenase, which has been recently
shown to catalyze the conversion of NO to nitrate in enzyme
assays, is also speciﬁc for NADH [19]. Moreover, this enzyme
is insensitive to DPI and cyanide, excluding its involvement in
endothelial NO consumption. A role of cytochrome P450 re-
ductase, which contributes to the oxidation of NO to nitrate by
human intestinal Caco-2 cells [21], is also unlikely because of
its very low aﬃnity for NADH (Km  15 mM [32]). The lack of
eﬀect of miconazole and econazole also excludes classical P450
enzymes as the heme component of the NO oxidation path-
way. Since NO consumption by Caco-2 cells is inhibited by
imidazoles and barely stimulated by NADH [21], the NO
metabolic pathway of endothelial cells appears to be diﬀerent
from that of intestinal cells.
Since the E. coli ﬂavohemoglobin also functions as a dihy-
dropteridine reductase [33,34], we tested for a role of thisenzyme by modulating endothelial tetrahydrobiopterin levels
with sepiapterin or 2,4-diamino-6-hydroxypyrimidine [35], but
none of the treatments aﬀected nitrate formation. Together
with the lack of nitrite oxidation by endothelial homogenates,
these data also argue against the involvement of a tetrahy-
drobiopterin-dependent conversion of nitrite to nitrate as
shown for hepatocytes [36]. Recently, an oxidation of NO to
nitrate has also been observed in cerebellar cells and brain
homogenates [22]. The molecular mechanism underlying this
reaction is unclear but apparently involves a protein, since the
eﬀect was virtually abolished by heat or protease treatment.
However, in contrast to our results obtained with endothelial
cells, NO consumption in the brain was insensitive to cyanide
and DPI, suggesting a distinct mechanism for the inactivation
of NO.
To further characterize the enzyme(s) involved in the en-
dothelial consumption of NO, we tried to purify the protein(s).
After centrifugation of the homogenate at 30 000 g, about
80% of the NO consuming activity was found in the particulate
fraction, indicating that in contrast to the soluble E. coli NO
dioxygenase, the mammalian analog is associated with the
plasma membrane or intracellular organelles. For solubiliza-
tion of the protein, several detergents including Triton X-100,
CHAPS and octyl-b-D-glycopyranoside were tested, but found
to be either ineﬀective or inapplicable due to inhibition of NO
consumption by homogenates (data not shown). Further
experiments are currently performed in our laboratory to es-
tablish an alternative approach for puriﬁcation and identiﬁ-
cation of the endothelial NO consuming enzyme (system).
In summary, our data demonstrate that endothelial cells
inactivate NO to nitrate in a unique NAD(P)H-, ﬂavin- and
heme-dependent reaction that may be catalyzed by a mem-
brane-associated analog of the bacterial NO dioxygenase. This
as yet unidentiﬁed enzyme (system) may contribute to the bi-
ological inactivation of NO in the vascular system. Since de-
creased NO bioavailability is a major cause of endothelial
dysfunction [37], identiﬁcation of the NO consumption path-
way is essential for the development of new therapeutic strat-
egies to interfere with pathological NO oxidation in
cardiovascular disease.
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